Trial Profile
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs RNS 60 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Revalesio
- 22 Feb 2024 Planned End Date changed from 1 Jun 2026 to 1 Nov 2026.
- 22 Feb 2024 Planned primary completion date changed from 1 Jun 2026 to 1 Nov 2026.
- 22 Feb 2024 Planned initiation date changed from 1 May 2024 to 1 Oct 2024.